Natural killer cells and cancer

Natural cytotoxicity, mediated by natural killer (NK) cells and cells with lymphokine‐activated killer (LAK) activity, is believed to play an important role in host anti‐cancer defense mechanisms.

[1]  Craig W. Reynolds,et al.  In vivo role of natural killer cells: involvement of large granular lymphocytes in the clearance of tumor cells in anti-asialo GM1-treated rats. , 1983, Journal of immunology.

[2]  S. Hilsenbeck,et al.  Optimal mastectomy timing. , 1992, Journal of the National Cancer Institute.

[3]  H. Bloom.  Hormone‐induced and spontaneous regression of metastatic renal cancer , 1973 .

[4]  J. Takasugi,et al.  Decline of natural nonselective cell-mediated cytotoxicity in patients with tumor progression. , 1977, Cancer research.

[5]  A. Rubbert,et al.  Functional characterization of tumor‐infiltrating lymphocytes, lymph‐node lymphocytes and peripheral‐blood lymphocytes from patients with breast cancer , 1991, International journal of cancer.

[6]  L. Lanier,et al.  The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes. , 1986, Journal of immunology.

[7]  D. Purtilo,et al.  Deficient natural killer cell activity in x-linked lymphoproliferative syndrome. , 1980, Science.

[8]  E. Holmes,et al.  Lymphoid cells infiltrating human pulmonary tumors: effect of intralesional BCG injection. , 1981, Journal of the National Cancer Institute.

[9]  D. Margulies,et al.  Host MHC class I molecules modulate in vivo expression of a NK cell receptor. , 1994, Journal of immunology.

[10]  D. Segal,et al.  CD44 is a cytotoxic triggering molecule in human peripheral blood NK cells. , 1994, Journal of immunology.

[11]  J. Johnson,et al.  Receptors for interleukin 2 on human squamous cell carcinoma cell lines and tumor in situ. , 1992, Cancer research.

[12]  S. Heys,et al.  Interleukin 2 treatment in colorectal cancer: current results and future prospects. , 1994, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[13]  M. Ferrarini,et al.  Characterization of cells from invaded lymph nodes in patients with solid tumors. Lymphokine requirement for tumor-specific lymphoproliferative response , 1987, The Journal of experimental medicine.

[14]  E. Holmes.  Immunology of Tumor Infiltrating Lymphocytes , 1985, Annals of surgery.

[15]  H. Pross,et al.  Surface markers on human b and t lymphocytes. VI. Cytotoxicity against cell lines as a functional marker for lymphocyte subpopulations , 1975, International journal of cancer.

[16]  W. Yokoyama.  Recognition structures on natural killer cells. , 1993, Current opinion in immunology.

[17]  J. Ayoub,et al.  Early inhibition of natural and interferon-activated killers in endometrial cancer patients treated with local radiotherapy. , 1987, Cancer detection and prevention.

[18]  D. Jones,et al.  Hormonal modulation of human natural killer cell activity in vitro. , 1985, Journal of reproductive immunology.

[19]  R. Oueslati,et al.  High interferon titer and defective NK‐cell activity in the circulation of nasopharyngeal carcinoma patients , 1989, International journal of cancer.

[20]  N. Grunnet,et al.  Natural Killer Cell Activity During Premedication, Anaesthesia and Surgery , 1983, Acta anaesthesiologica Scandinavica.

[21]  G. Trinchieri,et al.  Human natural killer cells analyzed by B73.1, a monoclonal antibody blocking Fc receptor functions. I. Characterization of the lymphocyte subset reactive with B73.1. , 1983, Journal of immunology.

[22]  P. Allavena,et al.  Defective natural killer activity within human ovarian tumors: low numbers of morphologically defined effectors present in situ. , 1983, Journal of the National Cancer Institute.

[23]  C. Taylor,et al.  Lymphokine-activated killer cell suppressor factor in malignant effusions. , 1991, Archives of surgery.

[24]  I. Fentiman,et al.  Timing of surgery during menstrual cycle and survival of premenopausal women with operable breast cancer , 1991, The Lancet.

[25]  R. Dillman.  The clinical experience with interleukin-2 in cancer therapy. , 1994, Cancer biotherapy.

[26]  C. Meijer,et al.  The development of anti-interleukin-2 (IL-2) antibodies in cancer patients treated with recombinant IL-2. , 1994, European journal of cancer.

[27]  F. Cerra,et al.  Natural killer cell activity: age, estrous- and circadian-stage dependence and inverse correlation with metastatic potential. , 1988, Journal of the National Cancer Institute.

[28]  U. Dianzani,et al.  CD8+CD11b+ peripheral blood T lymphocytes contain lymphokine‐activated killer cell precursors , 1989, European journal of immunology.

[29]  P. Kourilsky,et al.  Ly‐49‐independent inhibition of natural killer cell‐mediated cytotoxicity by a soluble major histocompatibility complex class I molecule , 1994, European journal of immunology.

[30]  H. Redmond,et al.  Cytokines in tumour therapy , 1992, The British journal of surgery.

[31]  S. Chouaib,et al.  Interleukin‐4 differentially regulates interleukin‐2‐mediated and CD2‐mediated induction of human lymphokine‐activated killer effectors , 1992, European journal of immunology.

[32]  A. Gritzapis,et al.  Elevated prostaglandin E2 production by monocytes is responsible for the depressed levels of natural killer and lymphokine‐activated killer cell function in patients with breast cancer , 1993, Cancer.

[33]  G. Martinelli,et al.  The prognostic significance of natural killer cytotoxicity in patients with colorectal cancer. , 1987, Archives of surgery.

[34]  G F Babcock,et al.  Subpopulations of human natural killer cells defined by expression of the Leu-7 (HNK-1) and Leu-11 (NK-15) antigens. , 1983, Journal of immunology.

[35]  Craig W. Reynolds,et al.  Direct evidence for the role of LGL in the inhibition of experimental tumor metastases. , 1985, Journal of immunology.

[36]  N. Holbrook,et al.  Direct suppression of natural killer activity in human peripheral blood leukocyte cultures by glucocorticoids and its modulation by interferon. , 1983, Cancer research.

[37]  M. Hansson,et al.  Human fetal thymus and bone marrow contain target cells for natural killer cells , 1981, European journal of immunology.

[38]  J. Griffin,et al.  Characterization of an antigen expressed by human natural killer cells. , 1983, Journal of immunology.

[39]  J. Roder,et al.  A new immunodeficiency disorder in humans involving NK cells , 1980, Nature.

[40]  E. Ciccone,et al.  P58 molecules as putative receptors for major histocompatibility complex (MHC) class I molecules in human natural killer (NK) cells. Anti-p58 antibodies reconstitute lysis of MHC class I-protected cells in NK clones displaying different specificities , 1993, The Journal of experimental medicine.

[41]  L. Lebeck,et al.  Rapid flow cytometric assay for the assessment of natural killer cell activity. , 1993, Journal of immunological methods.

[42]  W. Hong,et al.  Natural killer and lymphokine-activated killer activities in stomach cancer patients with special emphasis on the effect of 5-fluorouracil, adriamycin and mitomycin-C chemotherapy. , 1990, Japanese journal of clinical oncology.

[43]  S. Steinberg,et al.  Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. , 1993, Journal of the National Cancer Institute.

[44]  S. Grelli,et al.  Susceptibility to influenza A virus infection in mice immunosuppressed with cyclophosphamide. , 1991, Journal of chemotherapy.

[45]  R. Fisher,et al.  A phase I trial of continuous infusion interleukin-4 (IL-4) alone and following interleukin-2 (IL-2) in cancer patients. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[46]  K. Nagashima,et al.  Relationship of large and small CD3‐ CD56+ lymphocytes mediating NK‐associated activities , 1992, Journal of leukocyte biology.

[47]  S. Cole,et al.  P-glycoprotein-mediated multidrug resistance and cytotoxic effector cells. , 1992, Natural immunity.

[48]  J. Primrose,et al.  Peri‐operative modulation of cellular immunity in patients with colorectal cancer , 1993, Clinical and Experimental Immunology.

[49]  D. Strayer,et al.  Low natural cytotoxicity of peripheral blood mononuclear cells in individuals with high familial incidences of cancer. , 1984, Cancer Research.

[50]  P. Hersey,et al.  Low natural-killer-cell activity in familial melanoma patients and their relatives. , 1979, British Journal of Cancer.

[51]  R. Krishnaraj,et al.  Age-associated alterations in human natural killer cells. 2. Increased frequency of selective NK subsets. , 1988, Cellular immunology.

[52]  M. Lotze,et al.  Human lymphokine-activated killer cell activity. Role of IL-2, IL-4, and IL-7. , 1991, Archives of surgery.

[53]  D. Jones,et al.  Variation in natural killer activity in peripheral blood during the menstrual cycle. , 1985, British medical journal.

[54]  R. Oliver.  New views on rejection mechanisms and their relevance to interleukin-2 as a treatment for renal cell cancer. , 1991, European journal of cancer.

[55]  J. Daly,et al.  Natural killer cell stimulatory factor (NKSF) augments natural killer cell and antibody-dependent tumoricidal response against colon carcinoma cell lines. , 1991, The Journal of surgical research.

[56]  C. Balch,et al.  Patterns of human tumor-infiltrating lymphocytes in 120 human cancers. , 1990, Archives of surgery.

[57]  G. Parmiani.  An explanation of the variable clinical response to interleukin 2 and LAK cells. , 1990, Immunology today.

[58]  F. Takaku.  Clinical application of cytokines for cancer treatment. , 1994, Oncology.

[59]  P. Dellabona,et al.  On the relative roles of interleukin-2 and interleukin-10 in the generation of lymphokine-activated killer cell activity. , 1993, Cellular immunology.

[60]  J. Cohen,et al.  Cell-mediated cytotoxic mechanisms. , 1994, Current opinion in immunology.

[61]  G. Trinchieri,et al.  Response of resting human peripheral blood natural killer cells to interleukin 2 , 1984, The Journal of experimental medicine.

[62]  J. Miller,et al.  Differentiation of natural killer (NK) cells from human primitive marrow progenitors in a stroma-based long-term culture system: identification of a CD34+7+ NK progenitor. , 1994, Blood.

[63]  G. Trinchieri,et al.  Enhancing effect of natural killer cell stimulatory factor (NKSF/interleukin‐12) on cell‐mediated cytotoxicity against tumor‐derived and virus‐infected cells , 1993, European journal of immunology.

[64]  L. Lanier,et al.  Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis , 1986, The Journal of experimental medicine.

[65]  P. Guillou,et al.  Paradoxical effects of 5-FU/folinic acid on lymphokine-activated killer (LAK) cell induction in patients with colorectal cancer , 1990, British Journal of Cancer.

[66]  B. Perussia,et al.  Lymphokine-activated killer cells, natural killer cells and cytokines. , 1991, Current opinion in immunology.

[67]  P. Riley,et al.  Melanogenesis: a realistic target for antimelanoma therapy? , 1991, European journal of cancer.

[68]  N. Hanna.  Inhibition of experimental tumor metastasis by selective activation of natural killer cells. , 1982, Cancer research.

[69]  R. Blamey,et al.  Chemotherapy‐induced differential changes in lymphocyte subsets and natural‐killer‐cell function in patients with advanced breast cancer , 1993, International journal of cancer.

[70]  E. Lopez Hänninen,et al.  Interleukin-2 in combination with interferon-alpha and 5-fluorouracil for metastatic renal cell cancer. , 1993, European journal of cancer.

[71]  B. Petrini,et al.  Natural killer activity in peripheral lymphocyte population following local radiation therapy. , 1980, Acta radiologica. Oncology.

[72]  S. Heys,et al.  Interleukin-2 (IL-2) augments host cellular immune reactivity in the perioperative period in patients with malignant disease. , 1995, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[73]  L. Lanier,et al.  Functional and biochemical analysis of CD16 antigen on natural killer cells and granulocytes. , 1988, Journal of immunology.

[74]  F. Bonilla,et al.  Natural killer activity in patients with breast cancer. , 1990, European journal of gynaecological oncology.

[75]  J. Maroun,et al.  The standardization of NK cell assays for use in studies of biological response modifiers. , 1984, Journal of immunological methods.

[76]  M. Morita,et al.  Influence of preoperative treatment and surgical operation on immune function of patients with esophageal carcinoma , 1992, Journal of surgical oncology.

[77]  L. Wold,et al.  Lymphokine-activated killer (LAK) cell activity in tumor-infiltrating lymphocytes from non-small cell lung cancer. , 1989, American journal of clinical pathology.

[78]  A. Spira,et al.  Adjuvant treatment with polyadenylic-polyuridylic acid in operable breast cancer: updated results of a randomised trial. , 1984, British medical journal.

[79]  Welsh Rm.  Regulation of virus infections by natural killer cells. A review. , 1986 .

[80]  M. Shibuya,et al.  Effect of chemotherapy on natural-killer activity and antibody-dependent cell-mediated cytotoxicity in carcinoma of the lung. , 1982, British Journal of Cancer.

[81]  J. Brittenden,et al.  Natural cytotoxicity in breast cancer patients receiving neoadjuvant chemotherapy: effects of L-arginine supplementation. , 1994, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[82]  V. Seltzer,et al.  Natural cytotoxicity in malignant and premalignant cervical neoplasia and enhancement of cytotoxicity with interferon. , 1983, Gynecologic oncology.

[83]  T. Whiteside,et al.  Differential effects of IL12 and IL2 on expression and function of cellular adhesion molecules on purified human natural killer cells. , 1993, Cellular immunology.

[84]  J. Raus,et al.  Phenotypic analysis of tumor-infiltrating lymphocytes from human breast cancer. , 1992, Anticancer research.

[85]  R. Kempf,et al.  Effects of chemotherapeutic agents on the immune response. II. , 1985, Cancer investigation.

[86]  N. Papadopoulos,et al.  An improved fluorescence assay for the determination of lymphocyte-mediated cytotoxicity using flow cytometry. , 1994, Journal of immunological methods.

[87]  E. Aranda,et al.  Sera from patients with colon, breast and lung cancer induce resistance to lysis mediated by NK cytotoxic factors (NKCF). , 1991, British Journal of Cancer.

[88]  C. Snyderman,et al.  Functional and phenotypic analysis of lymphocytes in head and neck cancer. , 1991, Archives of otolaryngology--head & neck surgery.

[89]  W. Chang,et al.  Natural killer cell activity in patients with hepatocellular carcinoma relative to early development and tumor invasion , 1990, Cancer.

[90]  M. Ho,et al.  Natural killer cell activity in renal transplant recipients receiving cyclosporine , 1983, Infection and immunity.

[91]  T. Eberlein,et al.  The biological effects of immunosuppression on cellular immunotherapy. , 1992, Surgical oncology.

[92]  J. Ritz,et al.  Biology and clinical relevance of human natural killer cells. , 1990, Blood.

[93]  A. Chang,et al.  Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. , 1985, The New England journal of medicine.

[94]  A. Chang,et al.  The systemic administration of purified interleukin 2 enhances the ability of sensitized murine lymphocytes to cure a disseminated syngeneic lymphoma. , 1984, Journal of immunology.

[95]  S. Rosenberg,et al.  Immunotherapy and gene therapy of cancer. , 1991, Advances in surgery.

[96]  Mike Clarke,et al.  Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women , 1992 .

[97]  N. Mizushima,et al.  Relationship between natural killer activity and development of hepatocellular carcinoma in patients with cirrhosis of the liver. , 1987, Japanese journal of clinical oncology.

[98]  Mayo,et al.  Accelerated growth of testicular cancer after cytoreductive surgery , 1980 .

[99]  H. Groen,et al.  Effects of recombinant human interleukin-6 in cancer patients: a phase I-II study. , 1994, Blood.

[100]  A. Deleo,et al.  Monoclonal antibody to a triggering structure expressed on rat natural killer cells and adherent lymphokine-activated killer cells , 1989, The Journal of experimental medicine.

[101]  J. Johnson,et al.  The absence of lymphoid suppressor cells in tumor-involved lymph nodes of patients with head and neck cancer. , 1990, Cellular immunology.

[102]  P. Parham,et al.  NKB1: a natural killer cell receptor involved in the recognition of polymorphic HLA-B molecules , 1994, The Journal of experimental medicine.

[103]  H. J. Nielsen,et al.  Detrimental effects of perioperative blood transfusion , 1995, The British journal of surgery.

[104]  A. Thyss,et al.  Comparison of natural killer activity during the first and second halves of the menstrual cycle in women. , 1984, British Journal of Cancer.

[105]  H. Yamaue,et al.  Clinical and immunological evaluation of intraoperative radiation therapy for patients with unresectable pancreatic cancer , 1992, Journal of surgical oncology.

[106]  R. Burton,et al.  Definitive evidence that natural killer (NK) cells inhibit experimental tumor metastases in vivo. , 1981, Journal of immunology.

[107]  R. Krishnaraj,et al.  Age-associated alterations in human natural killer cells. 1. Increased activity as per conventional and kinetic analysis. , 1987, Clinical immunology and immunopathology.

[108]  J. Daley,et al.  Development of natural killer cells in human thymocyte culture: regulation by accessory cells , 1987, European journal of immunology.

[109]  D. Filippa,et al.  Natural cytotoxicity of peripheral blood lymphocytes and regional lymph node cells in breast cancer in women. , 1981, Journal of the National Cancer Institute.

[110]  J. Baley,et al.  Mechanisms of diminished natural killer cell activity in pregnant women and neonates. , 1985, Journal of immunology.

[111]  F. Bach,et al.  CD3 negative "small agranular lymphocytes" are natural killer cells. , 1991, Journal of immunology.

[112]  W. Seaman,et al.  NKR-P1, an activating molecule on rat natural killer cells, stimulates phosphoinositide turnover and a rise in intracellular calcium. , 1991, Journal of immunology.

[113]  G. Trinchieri,et al.  Biology of Natural Killer Cells , 1989, Advances in Immunology.

[114]  D. Schadendorf,et al.  Lysis of allogeneic and autologous melanoma cells by IL-7-induced lymphokine-activated killer cells. , 1994, British Journal of Cancer.

[115]  M. Provinciali,et al.  Influence of neoadjuvant polychemotherapy on natural killer cell activity in patients with locally advanced cervical squamous carcinoma. , 1994, Gynecologic oncology.

[116]  P. D. De Mulder,et al.  Subcutaneous recombinant interleukin-2 and alpha-interferon in patients with advanced renal cell carcinoma: results of a multicenter Phase II Study. , 2009, Cancer biotherapy.

[117]  M. Bertagnolli,et al.  Immunomodulatory Effects of Interleukin‐12 on Human Tumor‐Infiltrating Lymphocytes , 1993, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[118]  J. Ortaldo,et al.  Natural killer cells: their roles in defenses against disease. , 1981, Science.

[119]  L. Lanier,et al.  Human NKR-P1A. A disulfide-linked homodimer of the C-type lectin superfamily expressed by a subset of NK and T lymphocytes. , 1994, Journal of immunology.

[120]  C. Balch,et al.  Cellular immune defects in patients with melanoma involving interleukin-2-activated lymphocyte cytotoxicity and a serum suppressor factor. , 1985, Surgery.

[121]  J Dausset,et al.  Decline of natural killer cell activity in sublethally irradiated mice. , 1978, Journal of the National Cancer Institute.

[122]  Steven Wolinsky,et al.  Immune impairment and metastatic tumor growth. The need for an immunorestorative drug as an adjunct to surgery , 1979, Cancer.

[123]  M. Jones,et al.  The impact of interleukin-2 on survival in renal cancer: a multivariate analysis. , 1993, Cancer biotherapy.

[124]  W. Yokoyama.  Natural killer cell receptors. , 1998, Current opinion in immunology.

[125]  M. Moore,et al.  Suppressor cell activity of lymphocytes infiltrating human lung and breast tumours , 1979, International journal of cancer.

[126]  R. Giorda,et al.  Genomic structure and strain-specific expression of the natural killer cell receptor NKR-P1. , 1992, Journal of immunology.

[127]  N. Papadopoulos,et al.  Enhanced human lymphokine‐activated killer cell function after brief exposure to granulocyte‐macrophage–colony stimulating factor , 1995, Cancer.

[128]  L. Luistro,et al.  Antitumor and antimetastatic activity of interleukin 12 against murine tumors , 1993, The Journal of experimental medicine.

[129]  C. Fonatsch,et al.  Recombinant human interferon (IFN) alpha‐2b in chronic myelogenous leukaemia: dose dependency of response and frequency of neutralizing anti‐interferon antibodies , 1989, British journal of haematology.

[130]  R. Wiltrout,et al.  Role of NK cells in the control of metastatic spread and growth of tumor cells in mice , 1982, International journal of cancer.

[131]  J. Ortaldo,et al.  Mechanisms of target cell killing by natural killer cells. , 1989, Current opinion in immunology.

[132]  P. Guillou,et al.  Effects of low dose perioperative interferon on the surgically induced suppression of antitumour immune responses , 1988, The British journal of surgery.

[133]  D. de Ruysscher,et al.  Immunologic changes after loco-regional radiotherapy and fractionated total body irradiation (TBI) in mice. , 1989, International journal of radiation oncology, biology, physics.

[134]  C. Verfaillie,et al.  The generation of human natural killer cells from CD34+/DR- primitive progenitors in long-term bone marrow culture. , 1992, Blood.

[135]  J. D. Young,et al.  Cellular and humoral mechanisms of cytotoxicity: structural and functional analogies. , 1987, Advances in immunology.

[136]  S. Rosenberg,et al.  Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2. , 1985, Cancer research.

[137]  T. Vischer,et al.  alpha 2M-proteinase complexes are taken up by macrophages during joint inflammation. , 1982, Advances in experimental medicine and biology.

[138]  E. Thorsby,et al.  Long-term changes in natural killer activity after external pelvic radiotherapy. , 1981, International journal of radiation oncology, biology, physics.

[139]  M. Wainberg,et al.  Differential effects of chemotherapy-induced and HIV-1-induced immunocompromise on NK and LAK activities using breast cancer and HIV-1 seropositive patient populations. , 1991, Anticancer research.

[140]  R. Jaenisch,et al.  MHC class I deficiency: susceptibility to natural killer (NK) cells and impaired NK activity. , 1991, Science.

[141]  B. Campbell,et al.  Pharyngeal carcinoma and natural killer cell activity. , 1986, American journal of surgery.

[142]  G. Cloud,et al.  In vitro natural killer and lymphokine‐activated killer activity in patients with bronchogenic carcinoma , 1990, Cancer.

[143]  E. Lotzová,et al.  Genesis of human oncolytic natural killer cells from primitive CD34+CD33- bone marrow progenitors. , 1993, Journal of immunology.

[144]  J. Stephens,et al.  Human natural cytotoxicity in the blood and lymphoid organs of healthy donors and patients with malignant disease , 1978, International journal of cancer.

[145]  S. Schuval,et al.  Flow cytometric analysis of natural killer cell function as a clinical assay. , 1994, Cytometry.

[146]  S. Rosenberg,et al.  Clinical application of IL6 in cancer therapy. , 1992, Research in immunology.

[147]  P. Guillou,et al.  Simplified quantitation of cytotoxicity by integration of specific lysis against effector cell concentration at a constant target cell concentration and measuring the area under the curve. , 1991, Journal of immunological methods.

[148]  D. Longo,et al.  Loss of T-cell receptor zeta chain and p56lck in T-cells infiltrating human renal cell carcinoma. , 1993, Cancer research.

[149]  O. Eremin,et al.  Lymphocytes infiltrating human breast cancers lack K-cell activity and show low levels of NK-cell activity. , 1981, British Journal of Cancer.

[150]  P. Mcculloch,et al.  Effects of surgery on the generation of lymphokine‐activated killer cells in patients with breast cancer , 1993, The British journal of surgery.

[151]  S. Argov,et al.  Natural cytotoxicity in man: activity of lymph node and tumor‐infiltrating lymphocytes , 1977, European journal of immunology.

[152]  E. Gorelik,et al.  Depression of natural antitumor resistance of C57BL/6 mice by leukemogenic doses of radiation and restoration of resistance by transfer of bone marrow or spleen cells from normal, but not beige, syngeneic mice. , 1982, Journal of the National Cancer Institute.

[153]  S. Heys,et al.  Interleukin 2 therapy: current role in surgical oncological practice , 1993, The British journal of surgery.

[154]  P. Guillou,et al.  Suppression of the generation of lymphokine-activated killer (LAK) cells by serum-free supernatants of in vitro maintained tumour cell lines. , 1989, British Journal of Cancer.

[155]  O. Eremin,et al.  Killer cell (K) activity in human normal lymph node, regional tumour lymph node and inflammatory lymph node. , 1977, International archives of allergy and applied immunology.

[156]  N. Krishnan,et al.  Lymphokine‐activated killer‐cell function of lymphocytes from peripheral blood, regional lymph nodes and tumor tissues of patients with oral cancer , 1989, International journal of cancer.

[157]  L. Lanier,et al.  Identification of a common T/natural killer cell progenitor in human fetal thymus , 1994, The Journal of experimental medicine.

[158]  E. Holmes,et al.  Depression of natural killer cytotoxic activity in lymphocytes infiltrating human pulmonary tumors. , 1985, Cancer research.

[159]  F. Faure,et al.  MHC-unrestricted cytotoxicity. , 1990, Immunology today.

[160]  L. Kanz,et al.  The role of cytokines in oncology. , 1991, International journal of cell cloning.

[161]  J. Talmadge,et al.  Role of NK cells in tumour growth and metastasis in beige mice , 1980, Nature.

[162]  J. Jorda,et al.  Clinical implications of natural killer (NK) cytotoxicity in patients with squamous cell carcinoma of the uterine cervix. , 1990, Gynecologic oncology.

[163]  R. Sothern,et al.  Estrous influence on surgical cure of a mouse breast cancer , 1988, The Journal of experimental medicine.

[164]  C. Gahmberg,et al.  CD11a-c/CD18 and GP84 (LB-2) adhesion molecules on human large granular lymphocytes and their participation in natural killing. , 1988, Journal of immunology.

[165]  W. Yokoyama,et al.  Stimulation of murine natural killer (NK) cells by a monoclonal antibody specific for the NK1.1 antigen. IL-2-activated NK cells possess additional specific stimulation pathways. , 1991, Journal of immunology.

[166]  S. Rosenberg,et al.  A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. , 1986, Science.

[167]  R. Rees,et al.  The Nature of Enhanced Natural Killer Lymphocyte Cytotoxicity During Anesthesia and Surgery in Patients with Benign Disease and Cancer , 1984, Annals of surgery.

[168]  T. Eberlein,et al.  Regression of a disseminated syngeneic solid tumor by systemic transfer of lymphoid cells expanded in interleukin 2. , 1982, The Journal of experimental medicine.

[169]  G. Tjønnfjord,et al.  Thymic stromal cells support differentiation of natural killer cells from CD34+ bone marrow cells in vitro , 1995, European journal of haematology.

[170]  M. Matsuda,et al.  Decreased expression of the signal-transducing zeta chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma. , 1993, Cancer research.

[171]  M. Álvarez-Mon,et al.  Two different maturational stages of natural killer lymphocytes in human newborn infants. , 1991, The Journal of pediatrics.

[172]  L. Cozzaglio,et al.  Reduced natural killer cell activity and IL-2 production in malnourished cancer patients. , 1991, British Journal of Cancer.

[173]  S. Rosenberg,et al.  Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2 , 1985, The Journal of experimental medicine.

[174]  S. Steinberg,et al.  Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[175]  J. Ritz,et al.  Lymphokine-activated killer cell activity Characteristics of effector cells and their progenitors in blood and spleen. , 1987, Immunology today.

[176]  N. Ghossein,et al.  Natural cytotoxicity and interferon production in human cancer: deficient natural killer activity and normal interferon production in patients with advanced disease. , 1981, Journal of immunology.

[177]  J. Primrose,et al.  Perioperative immunotherapy with recombinant interleukin 2 in patients undergoing surgery for colorectal cancer. , 1992, Cancer research.

[178]  S. Schantz,et al.  An immunologic profile of young adults with head and neck cancer , 1989, Cancer.

[179]  W. Travis,et al.  Cellular mechanisms of the antitumor activity of recombinant IL-6 in mice. , 1992, Journal of immunology.

[180]  T. Suzuki,et al.  Evidence for the involvement of CD56 molecules in alloantigen-specific recognition by human natural killer cells , 1991, The Journal of experimental medicine.

[181]  C. Balch,et al.  Role of interleukin 2 and a serum suppressive factor on the induction of activated killer cells cytotoxic for autologous human melanoma cells. , 1985, Cancer research.

[182]  M. Volkenandt,et al.  Expansion of peripheral blood natural killer cells correlates with clinical outcome in cancer patients receiving recombinant subcutaneous interleukin-2 and interferon-alpha-2. , 1993, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[183]  J. Monson,et al.  Lymphokine activated killer (LAK) cells in patients with gastrointestinal cancer. , 1987, Gut.

[184]  W. Linehan,et al.  Experience with the Use of High‐Dose Interleukin‐2 in the Treatment of 652 Cancer Patients , 1989, Annals of surgery.

[185]  H. Inoue,et al.  Lymphokine‐activated killer cell function of peripheral blood mononuclear cells, spleen cells and regional lymph node cells in gastric cancer patients , 1994, Clinical and experimental immunology.

[186]  S. Ghali,et al.  In vitro stimulation of human NK activity by an estrogen antagonist (tamoxifen) , 1984, European journal of cancer & clinical oncology.

[187]  P. Hersey,et al.  No evidence for an association between natural killer cell activity and prognosis in melanoma patients. , 1983, Natural immunity and cell growth regulation.

[188]  Anthony Howell,et al.  Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. , 1992 .

[189]  P. Christiansen,et al.  Postoperative infection and natural killer cell function following blood transfusion in patients undergoing elective colorectal surgery , 1992, The British journal of surgery.

[190]  A. Uchida,et al.  Generation of suppressor cells for natural killer activity in cancer patients after surgery. , 1982, Journal of the National Cancer Institute.

[191]  H. Pross,et al.  Studies of human natural killer cells. I. in vivo parameters affecting normal cytotoxic function , 1982, International journal of cancer.

[192]  C. Balch,et al.  Characterization of human granular lymphocyte subpopulations expressing HNK‐1 (Leu‐7) and Leu‐11 antigens in the blood and lymphoid tissues from fetuses, neonates and adults , 1984, European journal of immunology.

[193]  E. Lotzová.  Definition and functions of natural killer cells. , 1993, Natural immunity.

[194]  K. Funa,et al.  Decreased natural killer cell activity and interferon production by leucocytes in patients with adenocarcinoma of the pancreas. , 1984, British Journal of Cancer.

[195]  R. Gallo,et al.  Selective in vitro growth of T lymphocytes from normal human bone marrows. , 1976, Science.

[196]  K. Kärre,et al.  "Anomalous" Thy-1+ killer cells in allogeneic and F1-anti-parental mixed leukocyte culture. Relation to natural killer cells and allospecific cytotoxic T lymphocytes , 1982, The Journal of experimental medicine.

[197]  J. Berry,et al.  Modulation of natural killer cell activity by tamoxifen in stage I post-menopausal breast cancer. , 1987, European journal of cancer & clinical oncology.

[198]  O. Carpén,et al.  Directed exocytosis in the NK-cell-mediated cytotoxicity. A review. , 1988, Natural immunity and cell growth regulation.

[199]  J. Ritz,et al.  Characterization of functional surface structures on human natural killer cells. , 1988, Advances in immunology.

[200]  E. Lotzová,et al.  Role of natural killer cells in cancer. , 1993, Natural immunity.

[201]  J. Saiki,et al.  Defects in natural killer cell activity and interferon response in human lung carcinoma and malignant melanoma. , 1984, Cancer research.

[202]  K. Yasumoto,et al.  Generation and expansion of lymphokine-activated killer cells from lymph node lymphocytes in human lung cancer. , 1989, European journal of cancer & clinical oncology.

[203]  A. Funahashi,et al.  Phenotype and function of natural killer cells in patients with bronchogenic carcinoma. , 1991, Cancer research.

[204]  L. Humphrey,et al.  Need for immunologic stimulators during immunosuppression produced by major cancer surgery. , 1985, Annals of surgery.

[205]  M. Schneider,et al.  Enhancement of tumor metastasis and suppression of natural killer cell activity by beta-estradiol treatment. , 1983, Journal of immunology.

[206]  G. Trinchieri,et al.  Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. , 1994, Blood.

[207]  A. Lichtenstein,et al.  Natural killer cell cytotoxicity in the peripheral blood, cervical lymph nodes, and tumor of head and neck cancer patients. , 1988, Cancer research.

[208]  R. Fox,et al.  Characterization of recirculating lymphocytes in rheumatoid arthritis patients: selective deficiency of natural killer cells in thoracic duct lymph. , 1984, Journal of immunology.

[209]  E. Ciccone,et al.  Human natural killer cells: origin, clonality, specificity, and receptors. , 1994, Advances in immunology.

[210]  H. Savage,et al.  Natural killer cells and metastases from pharyngeal carcinoma. , 1989, American journal of surgery.

[211]  P. Greenberg,et al.  Augmentation of the anti-tumor therapeutic efficacy of long-term cultured T lymphocytes by in vivo administration of purified interleukin 2 , 1982, The Journal of experimental medicine.

[212]  S. Einhorn,et al.  Human peripheral blood monocytes are susceptible to interferon-activated natural killer cells. , 1985, Journal of clinical & laboratory immunology.

[213]  W. Seaman,et al.  beta-Estradiol reduces natural killer cells in mice. , 1978, Journal of immunology.

[214]  S. Rosenberg,et al.  Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. , 1994, Journal of the National Cancer Institute.

[215]  C. Lozzio,et al.  Cytotoxicity of a factor isolated from human spleen. , 1973, Journal of the National Cancer Institute.

[216]  J. Ritz.  The role of natural killer cells in immune surveillance. , 1989, The New England journal of medicine.

[217]  P. Guillou,et al.  Expression of a suppressive p15E-related epitope in colorectal and gastric cancer. , 1993, British Journal of Cancer.

[218]  B. Shenton,et al.  The influence of surgical operations on components of the human immune system , 1985, The British journal of surgery.

[219]  J. Harris,et al.  Lymphokine‐activated killer cell induction in tumor‐infiltrating leukocytes from colon cancer patients , 1989, Cancer.

[220]  P. Tartter,et al.  Changes in peripheral T-cell subsets and natural-killer cytotoxicity in relation to colorectal cancer surgery. , 1986, Cancer detection and prevention.

[221]  R. Herberman,et al.  Modulation of natural killer cell activity by serum from cancer patients: preliminary results of a study of patients with colorectal adenocarcinoma or other types of cancer. , 1988, Cancer research.

[222]  S. Sone,et al.  Interleukin‐2‐inducible Killer Activity and Its Regulation by Blood Monocytes from Autologous Lymphocytes of Lung Cancer Patients , 1991, Japanese journal of cancer research : Gann.

[223]  G. Marshall,et al.  Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. , 1987, The New England journal of medicine.

[224]  R. Mertelsmann,et al.  The immunotherapy of human cancer with interleukin 2: present status and future directions. , 1991, Cancer investigation.

[225]  D. Blanchard,et al.  Lysis of human monocytes by lymphokine-activated killer cells. , 1988, Cellular immunology.